Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Manufacturing & Pharmacy Services Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Solutions Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Critical Care Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Oncology whitepaper web assets
    Oncology

    An early pioneer in oncology CGT, ICON has contributed to over 60 FDA/EMA approved therapies in the last 5 years.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications on the latest medical, scientific and clinical developments.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    thumbnail
    From here to where?

    Plotting a course to bring APAC-developed drugs to the world

    whitepaper
    From innovation to implementation: Navigating neurologic monoclonal antibody development

    Strategies for clinical readiness on day one

    thumbnail
    Making sense of the rapidly changing biosimilars landscape

    Strategies for adapting and achieving optimal market access

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media hub
    Website thumbnail image
    Meeting sites where they are: A connected, intelligence-powered operating model

    28 July 2026. Register today.

    banner
    ISPOR Europe 2026

    8 – 11 November 2026, Booth #1615

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Press releases
  4. ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials

ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials

Page tools
Share Share
Facebook

Share on Linkedin

Bluesky

Share on Bluesky

Facebook

Share on X

Facebook

Share on Facebook

Dublin, Ireland 28th July 2026 – ICON plc (NASDAQ: ICLR) today announced a multi-year collaboration with Anthropic to bring Claude’s AI capabilities across the clinical trial lifecycle. The collaboration further advances ICON’s digital innovation and AI strategy, and builds on Orbis – ICON’s secure, governed, agentic AI platform.

Through this collaboration, ICON will work closely with Anthropic’s Life Sciences research team to explore and apply cutting-edge technologies that can accelerate innovation across clinical development.

With support from Anthropic, ICON will develop four production capabilities within Orbis:

  • Site intelligence and study planning: powering ICON’s OneSearch and OnePlan tools with frontier model reasoning to sharpen site selection and study feasibility.
  • Orbis predictive intelligence: enabling real-time detection of enrolment risks, trends and operational signals across active studies.
  • Protocol optimisation: applying AI to protocol design and scenario modelling to reduce amendments and accelerate study startup.
  • Ecosystem integration: integrating ICON’s clinical expertise into client systems, allowing them to securely access ICON’s insights directly within Claude.

ICON will deploy Claude across the organisation through a targeted, role-based rollout: Claude Code for developers, Claude for knowledge teams, and Claude Science for scientific and clinical teams for maximum value creation

The collaboration with Anthropic directly supports the three foundational areas of ICON’s AI strategy: 

  • Anthropic’s frontier models will strengthen the intelligence layer that powers Orbis, connecting ICON’s expertise, data and AI across the trial lifecycle so that teams can make better and faster decisions for customers. 
  • The deployment of Claude capabilities across ICON’s developer and knowledge teams will drive productivity by automating high-volume, repeatable activity and redirecting human expertise to higher-value work. 
  • Working with Anthropic, ICON will develop and deploy domain-specific agents embedded directly within clinical development workflows.

Barry Balfe, Chief Executive Officer of ICON plc, commented: “We are determined to lead AI acceleration of clinical trials. Working with Anthropic gives us direct access to frontier AI capability and the people who build it. By combining ICON’s clinical development expertise, global delivery model and proprietary trial intelligence with Anthropic’s frontier AI capabilities, we believe we can help sponsors make better decisions earlier, execute studies with greater precision and ultimately accelerate the delivery of medicines to patients.”

Pip White, Head of Ireland, UK and Northern Europe, Anthropic added: “ AI holds real potential to address long-standing challenges in clinical development and make a measurable difference for patients. Far too often, the barrier to getting medicines to patients faster is operational, not scientific. Take study enrollment as an example - it’s one of the biggest bottlenecks in clinical development and causes delays in up to 80% of trials. This is exactly the kind of operational challenge that ICON's trial-delivery expertise, paired with Claude, is well suited to address."

About ICON plc

ICON plc is a world-leading clinical research organisation. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialisation and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organisations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 40,200 employees in 99 locations in 55 countries as at June 30, 2026. 

Learn more about the AI at ICON including our Orbis platform: 
www.iconplc.com/orbis

www.iconplc.com/ai

Media contacts:

ICON:

Lisa Henry (GMT time zone)

Weber Shandwick (PR adviser)

+447785 458203

lhenry@webershandwick.com 

 

ICON Press Office

iconnews@webershandwick.com 

In this section
In this section
  • Press releases
  • In the News
  • Mediakit
    • Facts and figures
    • ICON spokespeople
  • Awards
  • Events
    • Industry events
      • ASCO 2026
      • ISPOR EU 2026
    • Webinars
    • Workshops
  • Webinars
  • Social media hub

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media
Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
  • Social media hub
Socials
  • LinkedIn
  • Facebook
  • Instagram
  • YouTube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
  • Sitemap